Introduction: The resistance to antimicrobial agents among staphylococci is an increasing problem. This has led to renewed interest in the usage of macrolide-lincosamide-streptogramin B (MLSB) antibiotics to treat Staphylococcus aureus infections. Clinical failure has been reported due to multiple mechanisms that confer resistance to MLSB antibiotics.
INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA) are increasingly being reported as multidrug resistant with high resistance to macrolides (erythromycin, clarithromycin) and lincosamides (clindamycin, lincomycin), leaving very few therapeutic options . 1 Newer antibiotics like vancomycin,linezolid, and quinupristin-dalfopristin have been advocated in the management of such isolates, but recent reports of resistance to these agents raise real concerns over how long these uniform susceptibilities will hold good. [1] [2] [3] This has led to renewed interest in the usage of macrolide-lincosamide-streptogramin B (MLSB) antibiotics to treat S. aureus infections with, clindamycin being the preferred agent due to its excellent pharmacokinetic properties. 4, 5 MLSB antibiotics are structurally unrelated; however, they are related microbiologically because of their similar mode of action. They inhibit bacterial protein synthesis by binding to 23s rRNA, which is a part of large ribosomal subunit. They have a spectrum of activity directed against grampositive cocci, gramnegative cocci and intracellular bacteria such as chlamydiae and rickettsiae. 6 For years, macrolides have been used as an alternative to penicillin and cephalosporins in the treatment of infections caused by gram positive bacteria, but the worldwide development of macrolide resistance has now limited the use of these antibiotics. Macrolide resistance is by diverse mechanisms. The resistance to macrolide can be mediated by msr(A) gene coding for efflux mechanism or via erm gene encoding for enzymes that confer inducible or constitutive resistance to MLSB antibiotics. In constitutive resistance, r-RNA methylase is always produced (cMLSB); where as in inducible, methylase is produced only in the presence of an inducing agent (iMLSB). 7 Erythromycin is an effective inducer whereas clindamycin is a weak inducer. In vitro, S. aureus isolates with constitutive resistance are resistant to both erythromycin and clindamycin whereas those with inducible resistance are resistant to erythromycin and appear sensitive to clindamycin (iMLSB). 8 The treatment of patients harboring iMLSB staphylococci with clindamycin leads to the development of constitutive resistance, subsequently leading to therapeutic failure 9 The present study was aimed to detect inducible clindamycin resistance among S. aureus isolates and to study the relationship between clindamycin and methicillin resistance.
MATERIALS AND METHODS
The present study was a prospective study conducted during a period of 6 months from 1 st January 2015 to 30 th June 2015, on the patients admitted in Vadilal Sarabhai General Hospital, Ahmedabad. A total of 297 S. aureus isolates from various clinical specimens like pus, wound swab, aspirates, blood, body fluids, tissue, etc. were included in the study.General profile of patients is given in table-1.S. aureus isolates were identified by standard biochemical techniques. 10 Antimicrobial susceptibility testing was done by Kirby-Bauer's disc diffusion method using various antimicrobial agents like penicillin G (10Units), cefoxitin (30 mcg), gentamycin (10 mcg), chloramphenicol(30 mcg), tetracycline (30 mcg), erythromycin (15 mcg),cotrimoxazole (25mcg), ciprofloxacin (5 mcg), vancomycin(30 mcg), linezolid (30 mcg) as per CLSI guidelines. 11 For quality control (QC), S. aureus ATCC 25923 was used. For detection of methcillin resistance, 30 mcg of cefoxitin disc was placed and plates were incubated at 35°C for 24 h. Isolates with zone diameters ≤22 mm were labeled as methicillin resistant. l1 For detection of inducible clindamycin resistance, a disk approximation test was performed by placing a 2 mcg clindamycin disc from 21 mm away from the edge of a 15 mcg erythromycin disc. 11 Following overnight incubation at 37°C, three different phenotypes were appreciated and interpreted as follows:
1. MS phenotype: S. aureus isolates exhibiting resistance to erythromycin (zone size ≤13 mm), while sensitive to clindamycin (zone size ≥21 mm) and giving circular zone of inhibition around clindamycin (D test negative).
2. Inducible MLSB phenotype: iMLSB S. aureus isolates which showed resistance to erythromycin (zone size ≤13 mm) while being sensitive to clindamycin (zone size ≥21 mm) and giving D shaped zone of inhibition around clindamycin with flattening towards erythromycin disc (D test positive).
3. Constitutive MLSB phenotype: cMLSB S. aureus isolates which showed resistance to both erythromycin (zone size ≤13 mm) and clindamycin (zone size ≤14 mm) with circular shape zone of inhibition around clindamycin.
RESULTS
Of the 297 S. aureus isolates, majority was obtained from swabs 52% (153), pus 35% (104) followed by tissue, blood and body fluids 13% (40). All the S. aureus isolates were sensitive to vancomycin, and linezolid. 
